Summary
Guardant Health, Inc. (GH) presented its 2024 Annual Report on Form 10-K, highlighting significant revenue growth driven by its precision oncology testing business, which increased by 34% year-over-year to $687.9 million. This growth was fueled by a 34% rise in clinical testing revenue, attributed to increased sample volumes and improved reimbursement rates, particularly from Medicare for its Guardant360 LDT test. Biopharmaceutical revenue also saw a 31% increase. Despite top-line growth, the company continues to incur substantial net losses, with the 2024 net loss at $436.4 million, a slight improvement from $479.4 million in 2023. The company ended the year with a strong liquidity position, holding $944.2 million in cash, cash equivalents, restricted cash, and marketable debt securities, providing ample runway for continued investment in research and development, clinical studies, and commercial expansion. The company achieved a major milestone with the FDA approval and subsequent commercial launch of its Shield blood test for colorectal cancer screening in August 2024, making it the first FDA-approved blood test for primary colorectal cancer screening that also meets Medicare coverage requirements. This positions Guardant Health to address the critical early cancer detection market. Looking ahead, Guardant Health remains focused on expanding clinical utility, securing broader payer coverage and reimbursement, and growing its global commercial footprint. However, investors should remain aware of the significant risks outlined, including the ongoing unprofitability, dependence on reimbursement decisions, competitive pressures, and potential regulatory changes, particularly concerning Laboratory Developed Tests (LDTs).
Financial Highlights
57 data points| Revenue | $739.02M |
| Cost of Revenue | $289.80M |
| Gross Profit | $449.22M |
| R&D Expenses | $347.75M |
| Operating Expenses | $1.18B |
| Operating Income | -$443.59M |
| Interest Expense | $2.58M |
| Net Income | -$436.40M |
| EPS (Basic) | $-3.56 |
| EPS (Diluted) | $-3.56 |
| Shares Outstanding (Basic) | 122.75M |
| Shares Outstanding (Diluted) | 122.75M |
Key Highlights
- 1Total revenue increased by 31% to $739.0 million in 2024, driven by strong performance in precision oncology testing.
- 2Precision oncology testing revenue grew by 34% to $687.9 million, with clinical testing revenue up 34% and biopharmaceutical revenue up 31%.
- 3The company achieved a significant regulatory and commercial milestone with the FDA approval and launch of the Shield blood test for colorectal cancer screening.
- 4Net loss for 2024 was $436.4 million, an improvement from $479.4 million in 2023, though the company remains unprofitable.
- 5Guardant Health ended 2024 with a robust cash position of $944.2 million, providing liquidity for ongoing operations and investments.
- 6Increased sales and marketing expenses were driven by commercial team expansion and marketing efforts for new product launches, particularly the Shield test.
- 7Research and development expenses decreased by 5% to $347.8 million, mainly due to the nearing completion of the ECLIPSE clinical study.